ASTRAZENEKA's ALPHA Study met all key secondary endpoints at 12 weeks and demonstrated sustained efficacy through 48 weeks. Check out all key secondary data effortlessly at our Efortless Update. Follow this link to read more➡️: https://lnkd.in/gvsienwU
Efortless BioPharma Update’s Post
More Relevant Posts
-
When a high placebo response could mean a new drug is not effective, or it could be the result of an inappropriate trial population, the cause needs to be investigated. Analyzing trial data using IQVIA’s Subpopulation Optimization and Modeling Solution (SOMS) can eliminate variables and errors, leading to more informed and effective decision making. Visit our website for more information. https://bit.ly/3w2XOkp #clinicaltrials #dataanalysis
To view or add a comment, sign in
-
Check on our new (great!) tool for fast and efficient analysis of your AS-MS data!
“Tens of thousands of compounds seamlessly screened within hours. ”. Push your limits, explore Affinity Screen. Learn more: https://bit.ly/3sThwxn #medicinalchemistry #drugdiscovery #smallmolecule #ASMS #dataautomation #MgearsRocks
To view or add a comment, sign in
-
🎡 A centrifuge plays a crucial role in #clinicaltrials enabling the processing of important biological samples and the gathering of accurate data. In a process known as #centrifugation, they can isolate vital substances such as blood components or cellular materials for diagnostic testing within a clinical trial: https://lnkd.in/ebEZ7rJK
To view or add a comment, sign in
-
Want to learn more about the safety & efficacy of immediate complete revascularisation (ICR) and staged complete revascularisation (SCR) in patients presenting with ACS? 🤳Join Hala K. and Mirvat Alasnag next Tuesday, April 16th, for a Live chat on the substudy of the #BIOVASC randomised trial (to be published in the new issue coming out April 15). 🕰️Tune in at 6:00 PM on you favorite social media channel! #EIJonAir!
To view or add a comment, sign in
-
-
Biological samples are a critical part of just about every clinical trial. How do sample requirements and study implications change from phase to phase? Join the discussion in our latest webinar on November 30. Register here: https://lnkd.in/dkGfHQkC
To view or add a comment, sign in
-
-
Clinical trials rely on accurate, high-quality assessments to drive drug development success. Discover how blinded independent central reviews (BICRs) for imaging eligibility and disease progression are crucial for achieving this. Download our whitepaper to learn more: https://lnkd.in/enr9ZYNd #ClinicalTrials #BICR #MedicalImaging
To view or add a comment, sign in
-
-
What's wrong with the following actual chart titles on recently presented posters about Phase 1/2 data in ALS trials? "Drug X slows disease progression by 32%..." "Drug X stabilizes dyspnea through 24 weeks..." "Drug X improved...measures of speech function..." "Drug Y increases probability of complication-free survival" "Drug Y attenuated disease progression by 29.2%..." "Drug Y slowed decline of physical functions..." ...it's that these are all explicit claims about causation, when the most that can be claimed is correlation. This practice is unscientific and indefensible; at a bare minimum it inflates hope beyond what the data support. PIs and Sponsors need to do better.
To view or add a comment, sign in
-
🧬 Research shows the PaRTI-Seq gDNA-based assay effectively reduced host background and boosts microbial reads, enhancing sensitivity for accurate diagnosis. #Sepsis #mNGS #Innovation https://lnkd.in/gfznKcDx
To view or add a comment, sign in
-
-
Rare Disease Peeps…Fun Facts on how Science works… Read ALL 56 pages of this document before commenting…STUDY it before commenting… “Non-Inferiority Clinical Trials to Establish Effectiveness Guidance for Industry” https://lnkd.in/e5DSRg9q FACTS you NEED TO KNOW! Language in writing is IMPORTANT! #1 Science begins with a theory #2 Science is ALWAYS changing #3 Science changes as innovation progresses #4 Science can be biased and based on OBSERVATIONS, dependent on KNOWLEDGE, REPEATION, a PERSONS BELIEVE, EXPERIENCE and THEIR OWN PERCEPTIONS. Hince, the STAUS QUO is a MOVING TARGET and ALWAYS changes! The status quo needs to change sometimes! We do not grow without change, if we do not take calculated risks, we will NEVER know if it will work. Many do not know how drug effacacy is “graded”. Though we ALL want Safety, however, EFFICACY IS SUBJECTIVE! READ THAT AGAIN! The FDA has guidelines, Yes, only RECOMMENDATIONS of how effective a drug is. Currently, it is graded on “clinical” observation and data. My questions? Where does the PATIENT VOICE fit in? Does it matter? Where does REAL LIFE fit in? #PROMISINGPATHWAYS
To view or add a comment, sign in
-
-
TrialKey boasts a market-leading accuracy of over 90% based on precision and recall. Its accuracy consistency across trial phases and strong performance in predicting outcomes for rare or novel conditions make it a game-changer. TrialKey leverages extensive data on general trial practices, instilling confidence in researching rare conditions. Looking ahead, we're gathering data to develop a model for predicting FDA approvals, aiming to overcome current data transparency challenges. TrialKey is poised to revolutionise clinical research by providing reliable predictions and encouraging the exploration of rare conditions. #clinicalresearch #realworldevidence #rareconditions #healthcareinnovation #predictiveanalytics
TrialKey achieves market-leading accuracy of over 90%, with consistent performance across trial phases and strong predictions for rare and novel conditions, making it a game-changer in clinical research. Leveraging a vast dataset of 350,000 trials based on real-world evidence, TrialKey grows stronger with every new trial added. Our insights reveal that trial design significantly impacts success probability, as our algorithm finds the closest trial matches in terms of endpoint, disease state, and phase. Looking ahead, we're gathering data to develop a model for predicting FDA approvals, aiming to overcome current data transparency challenges. TrialKey is set to revolutionize clinical research by providing reliable predictions and encouraging the exploration of rare conditions. #clinicalresearch #realworldevidence #rareconditions #healthcareinnovation #predictiveanalytics
To view or add a comment, sign in
-